61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Sarepta Therapeutics Inc
Closed
Sector Healthcare
114.28 -0.57
Overview
Share price change
24h
Min
113.3
Max
116.23
Income | 27M 34M |
|---|---|
Sales | 104M 467M |
P/E Sector Avg | 166.52 59.526 |
EPS | 0.62 |
Profit margin | 7.194 |
EBITDA | 22M 49M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +57.43 upside |
Next Earnings | 26 Feb 2025 |
|---|
Market Cap | -398M 11B |
|---|---|
Previous open | 114.85 |
Previous close | 114.28 |
News Sentiment
By Acuity
25%
75%
46 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Sarepta Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sarepta Therapeutics Inc Forecast
Price Target
By TipRanks
57.43% upside
12 Months Forecast
Average 181.75 USD 57.43%
High 217 USD
Low 75 USD
Based on 19 Wall Street analysts offering 12 month price targets forSarepta Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
46 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.
